Statement by Ralph G. Neas, President and CEO, GPhA, Regarding H.B. 3734 in Massachusetts
Contact: Steve Arnoff
“GPhA applauds the Massachusetts state legislature for passing legislation allowing interchangeable biologics to be automatically substituted at the pharmacy. Laws that avoid unnecessary requirements around these new medicines not only increase patient access, but also will enable public and private payors to achieve significant savings by facilitating substitution of interchangeable biologics for more expensive versions. Massachusetts provides a compelling example of policy that embraces a practical approach.
As we get closer to the point when patients across the U.S. will be able to access these safe alternatives to costly brand name biologics, GPhA continues to support legislation that does not add burdens to current pharmacy practice and upholds the intent of the Biologics Price Competition and Innovation Act (BPCIA).”
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 84 percent of the prescriptions dispensed in the U.S. but consume just 27 percent of the total drug spending. Additional information is available at www.gphaonline.org. Follow us on twitter: @gpha.